Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX) have submitted an application to the US Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of a 10µg booster dose of their COVID-19 jab for children aged five to 11 years of age.
The submission included data from the Phase II/III trial in children aged five through 11 years who received a booster dose approximately six months after the second dose of the Pfizer-BioNTech COVID-19 Vaccine 10µg two-dose primary series, which was authorized under EUA for this age group in October 2021.
Data from the study demonstrated a strong immune response in this age group following a booster dose of the vaccine. There were no new safety signals reported.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze